NewAmsterdam Pharma N.V.
NAMS | NASDAQ
$23.43
+$0.85 (+3.76%)
Sep 22, 2026, 12:38 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -20.05 | -10.04 | -5.20 | -9.16 | -2.92 | -9.23 |
PEG Ratio | 0.63 | -0.53 | -0.06 | 0.14 | -0.02 | n/a |
PS Ratio | 178.34 | 53.22 | 65.13 | 2.01 | n/a | n/a |
PB Ratio | 5.87 | 3.20 | 3.18 | 0.48 | 3.06 | 1.48 |
P/FCF Ratio | -27.11 | -15.23 | -6.50 | 19.79 | -5.86 | -25.60 |
P/OCF Ratio | -27.16 | -15.29 | -6.50 | 19.38 | -5.86 | -25.65 |
OCF/S Ratio | -656.73 | -348.01 | -1K | 10.39 | n/a | n/a |
Debt / Equity Ratio | 0 | 0 | 0 | 0 | 0 | n/a |
Quick Ratio | 7.88 | 8.08 | 6.95 | 13.26 | 5.96 | 7.90 |
Current Ratio | 7.88 | 8.08 | 6.95 | 13.26 | 5.96 | 7.90 |
Asset Turnover | 0.03 | 0.05 | 0.04 | 0.21 | n/a | n/a |
Interest Coverage | n/a | n/a | -26.91 | -12.39 | -85.10 | n/a |
Return on Equity | -29.82% | -31.89% | -61.35% | -5.26% | -73.79% | -5.51% |
Return on Assets | -26.49% | -27.94% | -50.98% | -4.73% | -61.46% | -5.02% |
Return on Invested Capital | -33.01% | -23.26% | -61.55% | -0.80% | -61.57% | -4.75% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 99.74% | 100% | 100% | 100% | n/a | n/a |
Net Profit Margin | -905.74% | -530.25% | -1.26K% | -22.04% | n/a | n/a |
Pretax Profit Margin | -905.74% | -530.25% | -1.26K% | -22.04% | n/a | n/a |
Operating Profit Margin | -1K% | -386.91% | -1.3K% | -3.46% | n/a | n/a |
FCF Margin | -657.82% | -349.49% | -1K% | 10.17% | n/a | n/a |
EBITDA Margin | -1.08K% | -530% | -1.26K% | -21.75% | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove NAMS